-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Wp3hgS5LQED7w/9M6EKVxcUsKljtM03QLMF5gw8gJE/dc32j/mNxy5Toc6OGmgEr
 lLVuT/ho+bYK2H3Pw/2ieg==

<SEC-DOCUMENT>0001144204-06-039858.txt : 20060927
<SEC-HEADER>0001144204-06-039858.hdr.sgml : 20060927
<ACCEPTANCE-DATETIME>20060926173710
ACCESSION NUMBER:		0001144204-06-039858
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060926
FILED AS OF DATE:		20060927
DATE AS OF CHANGE:		20060926

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		061109576

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3

	MAIL ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v053563_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      September 26, 2006</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>750
      Lexington Avenue, 20</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>th</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      Floor</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>New
      York, New York 10022</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): <font face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): <font face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font face="Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;&#160;
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
      </font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt"><font size="2" face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><IMG SRC="logo.jpg"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Annual
      General Meeting ("AGM") Notice Posted to Shareholders </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>New
      York, New York, September 26, 2006</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
      XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biotechnology
      company focused on the acquisition, development and commercialization of
      pharmaceutical products for the treatment of infectious diseases, particularly
      the treatment of hepatitis C, has posted to shareholders a notice convening
      its
      AGM. The AGM will take place at the Conference Room at the Company&#8217;s Israeli
      offices at Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100,
      at
      4:00 p.m., on October 25, 2006. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">At
      the
      AGM it is proposed that: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">the
              annual reports for the year ended 31 December 2005 be received;
              </font></div>
          </td>
        </tr>

    </table>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Kesselman
              &amp; Kesselman (PricewaterhouseCoopers) be reappointed as the Company's
              auditors; and</font></div>
          </td>
        </tr>

    </table>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">Messrs
              Michael Weiss, Ben Zion Weiner and William Kennedy be re-appointed
              as
              Directors of the Company.</font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Contacts:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1
      (212) 531-5960</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      is
      engaged in the acquisition, development and commercialization of therapeutics
      for the treatment of infectious diseases, with a focus on hepatitis C. XTL
      is
      developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the
      hepatitis C virus polymerase - presently in Phase 1 clinical trials in patients
      with chronic hepatitis C. XTL is also developing XTL-6865 - a combination of
      two
      monoclonal antibodies against the hepatitis C virus - presently in Phase 1
      clinical trials in patients with chronic hepatitis C. XTL&#8217;s hepatitis C pipeline
      also includes several families of pre-clinical hepatitis C small molecules.
      XTL
      is publicly traded on the Nasdaq, London, and Tel-Aviv Stock Exchanges (NASDAQ:
      XTLB; LSE: XTL; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:
              September 26, 2006</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Ron
              Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Ron
              Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Chief
              Executive Officer</font></td>
          </tr>

      </table><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0OE17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`V.C`X.C$T(#(R.C`R
M.C`S``````.@`0`#`````?__``"@`@`$`````0```+2@`P`$`````0```$T`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```*MP````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`#<`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/3[<S$I?Z=U]=;XW;7O:TP=-VUQ\ER?U]^N.5T7$Q&]
M(=4^W.=8/M)BQK&TAF\,8#L=:Y]K/I_0_P!&B?XQ?JJSK?2OMF-2+.I8`+Z@
M!+K*^;L7^5_I*/\`AO\`CK%P7U(LZ/EY/_-_K-8LZ?U!XLQ""6>EEANQKJWU
MNK=7]KI_1?R[:Z&*?%CB1QGU</S08IS(/#MQ?+)[OZA_7'(ZUA90ZLZME^$^
MMIR!%;'MM#O3W-)VMNW5/^C_`"%U`ZA@.W%N340P;GP]IALQN=K[6KQOZZY'
M2\?)_P";O1ZA7TSIMA=<)+S;F$>G;98^QSW6NQV?JS/^$];_`(-=?TO_`!?W
M4?4G,Z>UM5?6.K,:^]UDAC(<Q]6,75L<[;2QON]G](]1+)CCI*^$3.D?#NJ$
MSK'YN$:R_K/:?M+IW_<JG_MQO_DDOVET[_N53_VXW_R2\IN_Q3=>IJ?<^[`V
MUM+W0;)AHW:?H%S71.C6=;ZC1T[$%5=V2'%CK1#!L8;G;O3:]WT6_NHC!`@D
M9+`WT0<T@0#`ZOO?[2Z=_P!RJ?\`MQO_`))3JS,2Y^RF^NQ\3M8]KC'C#2O(
M>H?XK^M].P,C/OMPG4XM3[K&L-A<6L!>X,W4-;N]J-_BF8P?6BXM:!^HV<`#
M_"XZ!PQX3*,^+A\$C*>(1,:M]>4++J:@#:]M8/&X@?\`5*:Y'_&$`<?"D`^]
M_P"1J9AQ^YDC"ZXNJ.8S>SBEDKBX:T^KUR2#=E8N.&_:+JZ=WT=[@V?AN(1&
M/98T/K<'L=PYID'YA1T=V6Q=7KV8NOI;8*G6-%CN&$@.,_R418N;]7ZLKKE'
M579&Q]&R*=H,["\_3W;O=O\`W5M)TA$"/#*['JT^4K82F3+BCP@&HF[XH_O*
M25=N?@OL])N14ZR8V![2Z?ZL[E80((W"X$'8@^3_`/_0]57C?^,'H+>A=?;E
M8;]E.>79-+6':^JYK@Z[9M]S6>HYE]#_`,Q_Z/\`P:]=SL[&Z?AW9V6\58^.
MPV6O/9K1/]IW[K5XK99U'ZZ_6ML[FOS+-E;3[OL^*R7>+6_H:MUC_P#395G_
M``BL<L""9740/4PYZ($=Y$^EU/\`%ET/'ZGUJSJ&4]KQTW;;703+W7/)+,A[
M3]*NF'._\,_\6O75X9B9/4?J9]:'DC=;A6&K(K&@NQW0_P!O_'5>GD4?N7+V
MW#R\?-Q:<S%>+*,AC;*GCNUPW-0YD'B$MXD>E.`CAX=I`^IAU'_D_*_XFS_J
M7+QK_%M_XKNE_P!2[_SQ8O9>H_\`)^5_Q-G_`%+EXU_BV_\`%=TO^I=_YXL1
MP_S>7R_8C+\^/S?5_K=_XENK?^$[_P#SVY><_P"*?_Q3V_\`A&S_`,^8Z]&^
MMW_B6ZM_X3O_`//;EYU_BG_\4]W_`(1L_P#/N,EB_F<BI_SL/J^N+DO\8$>A
MA3QO?/\`FA=:N1_QA?T;#/;?9/\`FA#E/Y^'U_Z+'\0_W+D\A_THI<'ZIT]1
MH;U'K%MMN9E@6.`=M#`X36SZ/YK/["H&J[ZI]<I95:Y_3\J-[7?NSL?O#?;Z
MM$ML]1K?H+M*"QU-;F:L+06GRC1<E]??TN3T_'KUM=ZD`<^\U,9_T@I<&6>3
M)[<C>.0D.']&``TX?W>%@YK!##A&7&*RP,2)_I9)2EZN+][C9=8`_P"?'3S&
MNVO\MR77LK,ZQUMOU?Q+/2QV$?:'#N0/4L=9'TJZF?0J_/O^FEUC_P`6_3_Z
MM?Y;E'HY]#Z[YU=VC[?5%?\`:-=[?_`0GQTC&=7*&'BC_>XOF_P6.1)G/'9$
M<O,"$Z_<X/D_PV[9]1.C''].MUK+0-+BX.,_RZX%>W^KZ:#]5.HYU&;=T'J#
MM[\<$TO))(VD;J@YWN?7L=ZM'_!KJEQV+%WU_N?5[FU[MY';;4REW_@IVJ+'
M.66&6.0\0C$SB9?HRCV9\V.&#)@GB'`93&*48[3QR_>']5__T=[_`!A=.^M?
M6C3TWI6)OZ<R+<BSUJV>K9/Z.KT['M?Z5'\[_P`)=L_T"-_B\^J.1T+'OS>I
M5AG4LH[/3!:_TJ6'VL]2O<W=>_\`36;7_P"@_P!&NQ24GNRX.`4!^*W@'%Q=
M7BO\8GU.RNM-Q^H=*J%G4*?T-M>YK/4I/N:=]A:S?CV>YG\BVW^0G_Q>=/\`
MK3T:N[IG5\0UX!F[&M]:M_IO)_2X_IUV/=Z=O\^S;]"SUO\`2KM$DO=EP<!H
MC\5<`XN+J@S:WVX=]58W/?6]K1Q)+2&\KS/ZD?4KZS]*^L>!FY^&*<:AM@ML
M]6I\%U3ZF>RM[G_3<O4TD(Y#&,HBO5H52@)$$_HZN=]8L3(S>@=1P\5GJ9&1
MC6UU,D-ESF.:QNY\-;[EY/7]0/KQ4=U6$:G1!<S)J88_=W5W-7M*2./-*`(`
M!ONB>,3()O3L^,_\R/\`&#_H+O\`V-;_`.]"O])^IGURKML^W8[W,(:&;\EE
MD'=[]NZU^WVKU=)2#FY@V!'[&+)RL,D#"4I5+Q[>IY2L_6SHC/L5&.WJ.(PQ
MCVGZ0;^:QP#VN;L_E?V+-BGTKH75,OJ@ZQUTAME9!IQP08(_F_HES:ZJ=VZM
MF[U/5_26_P#"=0D@>8E1J,8RD*E.(]10.4C<>*<YP@;ACD?1']W^]P_HO.=2
MZ3U"_P"M6'U"JK=BTM8++-S1$&S=["[?^?\`NJ7UB^KN1F9%?4^F/%6?3$B=
MN_;]!P?_`*5OT??[+&+H4DT9Y@Q(KT1X/[T?ZR3RN,C(#9]R7N'7Y9]X/)NZ
ME]=[:CC-P&UVD;3D"!'\MNZWTMRT?JW]7OV2Q]^0\6YMXBQPU#6SNV-<[WOW
MN]]K_P`];:2,LY,3&,8P$OFX?TE0Y8"8G.<LLH_)QGY/+A_2?__2]527RJDD
MI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JD
ME\JI)*?_V?_M$()0:&]T;W-H;W`@,RXP`#A"24T$)0``````$```````````
M```````````X0DE-`^T``````!``2`````$``0!(`````0`!.$))300F````
M```.`````````````#^````X0DE-!`T```````0```!X.$))3009```````$
M````'CA"24T#\P``````"0```````````0`X0DE-!`H```````$``#A"24TG
M$```````"@`!``````````$X0DE-`_4``````$@`+V9F``$`;&9F``8`````
M``$`+V9F``$`H9F:``8```````$`,@````$`6@````8```````$`-0````$`
M+0````8```````$X0DE-`_@``````'```/__________________________
M__\#Z`````#_____________________________`^@`````____________
M_________________P/H`````/____________________________\#Z```
M.$))300(```````0`````0```D````)``````#A"24T$'@``````!``````X
M0DE-!!H``````TD````&``````````````!-````M`````H`6`!4`$P`0@!I
M`&\`3`!O`&<`;P````$``````````````````````````0``````````````
MM````$T``````````````````````0`````````````````````````0````
M`0```````&YU;&P````"````!F)O=6YD<T]B:F,````!````````4F-T,0``
M``0`````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N
M9P```$T`````4F=H=&QO;F<```"T````!G-L:6-E<U9L3',````!3V)J8P``
M``$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````````!V=R;W5P
M241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R:6=I;@````UA
M=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y<&4`````26UG
M(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG
M``````````!,969T;&]N9P``````````0G1O;6QO;F<```!-`````%)G:'1L
M;VYG````M`````-U<FQ415A4`````0```````&YU;&Q415A4`````0``````
M`$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!```````.8V5L;%1E
M>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!```````):&]R>D%L
M:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L=`````EV97)T
M06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A=6QT````"V)G
M0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90````!.;VYE````
M"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG``````````QB
M;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO;F<``````#A"
M24T$$0```````0$`.$))3004```````$`````SA"24T$#``````*TP````$`
M``"`````-P```8```%*````*MP`8``'_V/_@`!!*1DE&``$"`0!(`$@``/_M
M``Q!9&]B95]#30`"_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+
M"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`-P"``P$B``(1`0,1
M`?_=``0`"/_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!
M`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1
M`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R
M@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2
M!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+2
M1)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6
MYO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]/MS,2E_IW7UUOC=M>]K3!TW
M;7'R7)_7WZXY71<3$;TAU3[<YU@^TF+&L;2&;PQ@.QUKGVL^G]#_`$:)_C%^
MJK.M]*^V8U(LZE@`OJ`$NLKYNQ?Y7^DH_P"&_P".L7!?4BSH^7D_\W^LUBSI
M_4'BS$()9Z66&[&NK?6ZMU?VNG]%_+MKH8I\6.)'&?5P_-!BG,@\.W%\LGN_
MJ']<<CK6%E#JSJV7X3ZVG($5L>VT.]/<TG:V[=4_Z/\`(74#J&`[<6Y-1#!N
M?#VF&S&YVOM:O&_KKD=+Q\G_`)N]'J%?3.FV%UPDO-N81Z=MEC['/=:['9^K
M,_X3UO\`@UU_2_\`%_=1]2<SI[6U5]8ZLQK[W62&,AS'U8Q=6QSMM+&^[V?T
MCU$LF..DKX1,Z1\.ZH3.L?FX1K+^L]I^TNG?]RJ?^W&_^22_:73O^Y5/_;C?
M_)+RF[_%-UZFI]S[L#;6TO=!LF&C=I^@7-=$Z-9UOJ-'3L055W9(<6.M$,&Q
MAN=N]-KW?1;^ZB,$""1DL#?1!S2!`,#J^]_M+IW_`'*I_P"W&_\`DE.K,Q+G
M[*;Z['Q.UCVN,>,-*\AZA_BOZWT[`R,^^W"=3BU/NL:PV%Q:P%[@S=0UN[VH
MW^*9C!]:+BUH'ZC9P`/\+CH'#'A,HSXN'P2,IXA$QJWUY0LNIJ`-KVU@\;B!
M_P!4IKD?\80!Q\*0#[W_`)&IF''[F2,+KBZHYC-[.*62N+AK3ZO7)(-V5BXX
M;]HNKIW?1WN#9^&XA$8]EC0^MP>QW#FF0?F%'1W9;%U>O9BZ^EM@J=8T6.X8
M2`XS_)1%BYOU?JRNN4=5=D;'T;(IV@SL+S]/=N]V_P#=6TG2$0(\,KL>K3Y2
MMA*9,N*/"`:B;OBC^\I)5VY^"^STFY%3K)C8'M+I_JSN5A`@C<+@0=B#Y/\`
M_]#U5>-_XP>@MZ%U]N5AOV4YY=DTM8=KZKFN#KMFWW-9ZCF7T/\`S'_H_P#!
MKUW.SL;I^'=G9;Q5CX[#9:\]FM$_VG?NM7BMEG4?KK]:VSN:_,LV5M/N^SXK
M)=XM;^AJW6/_`--E6?\`"*QRP()E=1`]3#GH@1WD3Z74_P`670\?J?6K.H93
MVO'3=MM=!,O=<\DLR'M/TJZ8<[_PS_Q:]=7AF)D]1^IGUH>2-UN%8:LBL:"[
M'=#_`&_\=5Z>11^Y<O;</+Q\W%IS,5XLHR&-LJ>.[7#<U#F0>(2WB1Z4X".'
MAVD#ZF'4?^3\K_B;/^I<O&O\6W_BNZ7_`%+O_/%B]EZC_P`GY7_$V?\`4N7C
M7^+;_P`5W2_ZEW_GBQ'#_-Y?+]B,OSX_-]7^MW_B6ZM_X3O_`//;EYS_`(I_
M_%/;_P"$;/\`SYCKT;ZW?^);JW_A._\`\]N7G7^*?_Q3W?\`A&S_`,^XR6+^
M9R*G_.P^KZXN2_Q@1Z&%/&]\_P":%UJY'_&%_1L,]M]D_P":$.4_GX?7_HL?
MQ#_<N3R'_2BEP?JG3U&AO4>L6VVYF6!8X!VT,#A-;/H_FL_L*@:KOJGUREE5
MKG]/RHWM=^[.Q^\-]OJT2VSU&M^@NTH+'4UN9JPM!:?*-%R7U]_2Y/3\>O6U
MWJ0!S[S4QG_2"EP99Y,GMR-XY"0X?T8`#3A_=X6#FL$,.$9<8K+`Q(G^EDE*
M7JXOWN-EU@#_`)\=/,:[:_RW)=>RLSK'6V_5_$L]+'81]H<.Y`]2QUD?2KJ9
M]"K\^_Z:76/_`!;]/_JU_EN4>CGT/KOG5W:/M]45_P!HUWM_\!"?'2,9U<H8
M>*/][B^;_!8Y$F<\=D1R\P(3K]S@^3_#;MGU$Z,<?TZW6LM`TN+@XS_+K@5[
M?ZOIH/U4ZCG49MW0>H.WOQP32\DDC:1NJ#G>Y]>QWJT?\&NJ7'8L7?7^Y]7N
M;7NWD=MM3*7?^"G:HL<Y9898Y#Q",3.)E^C*/9GS8X8,F">(<!E,8I1CM/'+
M]X?U7__1WO\`&%T[ZU]:-/3>E8F_IS(MR+/6K9ZMD_HZO3L>U_I4?SO_``EV
MS_0(W^+SZHY'0L>_-ZE6&=2RCL],%K_2I8?:SU*]S=U[_P!-9M?_`*#_`$:[
M%)2>[+@X!0'XK>`<7%U>*_QB?4[*ZTW'ZATJH6=0I_0VU[FL]2D^YIWV%K-^
M/9[F?R+;?Y"?_%YT_P"M/1J[NF=7Q#7@&;L:WUJW^F\G]+C^G78]WIV_S[-O
MT+/6_P!*NT22]V7!P&B/Q5P#BXNJ#-K?;AWU5C<]];VM'$DM(;RO,_J1]2OK
M/TKZQX&;GX8IQJ&V"VSU:GP75/J9[*WN?]-R]320CD,8RB*]6A5*`D03^CJY
MWUBQ,C-Z!U'#Q6>ID9&-;74R0V7.8YK&[GPUON7D]?U`^O%1W581J=$%S,FI
MAC]W=7<U>TI(X\TH`@`&^Z)XQ,@F].SXS_S(_P`8/^@N_P#8UO\`[T*_TGZF
M?7*NVS[=CO<PAH9OR660=WOV[K7[?:O5TE(.;F#8$?L8LG*PR0,)2E4O'MZG
ME*S];.B,^Q48[>HXC#&/:?I!OYK'`/:YNS^5_8LV*?2NA=4R^J#K'72&V5D&
MG'!!@C^;^B7-KJIW;JV;O4]7]);_`,)U"2!YB5&HQC*0J4XCU%`Y2-QXISG"
M!N&.1]$?W?[W#^B\YU+I/4+_`*U8?4*JMV+2U@LLW-$0;-WL+M_Y_P"ZI?6+
MZNY&9D5]3Z8\59],2)V[]OT'!_\`I6_1]_LL8NA231GF#$BO1'@_O1_K)/*X
MR,@-GW)>X=?EGW@\F[J7UWMJ.,W`;7:1M.0($?RV[K?2W+1^K?U>_9+'WY#Q
M;FWB+'#4-;.[8USO>_>[WVO_`#UMI(RSDQ,8QC`2^;A_25#E@)B<YRRRC\G&
M?D\N'])__]+U5)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JD
ME\JI)*?JI)?*J22GZJ27RJDDI__9`#A"24T$(0``````50````$!````#P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``
M4`!H`&\`=`!O`',`:`!O`'``(``W`"X`,`````$`.$))300&```````'``0`
M```!`0#_X1)(:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K
M970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_
M/@H\/V%D;V)E+7AA<"UF:6QT97)S(&5S8STB0U(B/SX*/'@Z>&%P;65T82!X
M;6QN<SIX/2=A9&]B93IN<SIM971A+R<@>#IX87!T:STG6$U0('1O;VQK:70@
M,BXX+C(M,S,L(&9R86UE=V]R:R`Q+C4G/@H\<F1F.E)$1B!X;6QN<SIR9&8]
M)VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,G
M('AM;&YS.FE8/2=H='1P.B\O;G,N861O8F4N8V]M+VE8+S$N,"\G/@H*(#QR
M9&8Z1&5S8W)I<'1I;VX@86)O=70])W5U:60Z9C$S-3`W8C0M,F,P,2TQ,61B
M+3@W93$M9&%C.#,Q9C9E-F8P)PH@('AM;&YS.GAA<$U-/2=H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O;6TO)SX*("`\>&%P34TZ1&]C=6UE;G1)1#YA
M9&]B93ID;V-I9#IP:&]T;W-H;W`Z9C$S-3`W8C(M,F,P,2TQ,61B+3@W93$M
M9&%C.#,Q9C9E-F8P/"]X87!-33I$;V-U;65N=$E$/@H@/"]R9&8Z1&5S8W)I
M<'1I;VX^"@H\+W)D9CI21$8^"CPO>#IX87!M971A/@H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T(&5N
M9#TG=R<_/O_N``Y!9&]B90!D``````'_VP"$``8$!`0%!`8%!08)!@4&"0L(
M!@8("PP*"@L*"@P0#`P,#`P,$`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P!!P<'#0P-&!`0&!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`$T`M`,!$0`"$0$#$0'_W0`$
M`!?_Q`&B````!P$!`0$!```````````$!0,"!@$`!P@)"@L!``("`P$!`0$!
M``````````$``@,$!08'"`D*"Q```@$#`P($`@8'`P0"!@)S`0(#$00`!2$2
M,4%1!A-A(G&!%#*1H0<5L4(CP5+1X3,68O`D<H+Q)4,T4Y*BLF-SPC5$)Y.C
MLS875&1TP]+B"":#"0H8&82414:DM%;352@:\N/SQ-3D]&5UA96EM<75Y?5F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@I.4E9:7F)F:FY
MR=GI^2HZ2EIJ>HJ:JKK*VNKZ$0`"`@$"`P4%!`4&!`@#`VT!``(1`P0A$C%!
M!5$382(&<8&1,J&Q\!3!T>$C0A528G+Q,R0T0X(6DE,EHF.RP@=STC7B1(,7
M5),("0H8&28V11HG9'15-_*CL\,H*=/C\X24I+3$U.3T976%E:6UQ=7E]496
M9G:&EJ:VQM;F]D=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)
MV>GY*CI*6FIZBIJJNLK:ZOK_V@`,`P$``A$#$0`_`/5.*NQ5X!^9/_.3=QH7
MF2ZT3R_ID-T-/E,-U>73L%:1-G6-4[*?AY,<V&#0\4;D>;A9=9PF@]%_*3\T
M['\P=#FNTM_J>HV3B*_L^7,*6%5=&VJCT.8^HP'&:Z-^',)BV=9CMSL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_`/_0[A^<&I^>]'\JOK/E
M!XC<:>3+?6TL0E+VX'Q,FX^*/[7^KE^GC"4JEU:<QD(W%\]67_.47YF1WD$E
MVUG/:+(K7$*VX1GC!^)5;E\+%>AS9'L^%;6X`ULKW4O//Y/>;=6UF;S-Y3LF
MUGR]K[F_L98&7U$%Q\9CD1BI!1B5Y8<6IB!PR],HHRZ>1/%'<23BRN-<_)#R
M9*TK0IYV\RRQM#9-29+6SMZU>2AXL[LQ7_KELA(#43V^B+,7@C_2DO\`)7YX
M?G/YM\S6.@Z?-9"6Z?\`>R_501%"N\DC?%T5<CETF*$>(VG%J<DY4R'\Z_SI
M\^^3O.OZ%TB>V^J+:0RDS0!V,CUY&M1UITRO3:6$X66>HU,H2H,"_P"AG?S6
M_P!_V7_2*/\`FK,C\AC\VC\[-W_0SOYK?[_LO^D4?\U8_D,?FOYV;O\`H9W\
MUO\`?]E_TBC_`)JQ_(8_-?SLW?\`0SOYK?[_`++_`*11_P`U8_D,?FOYV;,?
MRC_/;\P?-'Y@:;HFJS6K6%T)C*L4`1_@C+"C<C3<93J-)"$"0W:?4RG*B^D\
MUCL'8J\S_-;S[YA\M:G9V^EO$L4\#2/ZD?,\@U-MQFV[-T4,T297L7G.VNT\
MNFG$0JI!Z'I<\EQIEI<2D&2:&.1R!0<F0$[?3FLR1J1'F[_#(R@">L0B<@V.
MQ5Y3^9WYB^9?+WF-+#3985MS;I*1)&'/)B0=R?;-SV?H<>6!E*[MYCMCM;-I
M\HC"JX>YZA92O-9P2ON\D:,Q'2K*"<T\A1(>DQRN(/DK8&;L5=BKL5?_T?5#
MHKHR.`R,"&4BH(/4$8J^*?SP_+67R5YNE-M&1H6IEI]-D`^%"35X*^,9^S_Q
M7QS>Z7/XD=_J#IM5AX)>3T#_`)QM_->TTS3=0\M:]<B&RL89+_3YY#0+&GQ3
MQ;_\C(U_ULQM;IR2)!R-)GH47CWYA^=+SSEYMOM>N*K',W"SA._IVZ;1I\Z?
M$W^6V9V#$(1`<3-D,Y6^G?\`G'C\L1Y5\LC6-1@]/7]84/*'^U#;UK'%[$_;
MD_RO]7-3K,_'*A],79:7#P1L\RR;S9^3OD'S7JYU?7+![B^,:Q&032QC@GV1
MQ1@.^58]3.`H%LG@C(V6.:M_SCO^5%OI5[<1:4XEA@EDC/UB8T94)!W;Q&6Q
MUF0D;M<M+"N3XZJ>%>],W;J.K[!T#_G'K\JKS0M-NY]*=I[BUAEE;ZQ,*N\:
MLQH&\3FDGK,@D=W;QTL"!LP'\_\`\I?(OE#R;;ZEH-BUM>27L<+2--)(.#*Q
M(H[$=LR=)J)SE4BT:G!&,;#!/^<>?_)NZ+_JW'_)ELR-;_=EHT?UOM7-$[AV
M*O$?S]_X[>F?\PK_`/)PYT/8OTR_K/&>T_\`>0_J_I>B3>=/+GEW0M-&IW0C
MF>UA:.W0%Y6'`;A1V^>:L:3)EG+A'\1>@EK\.GQ1XS1X(^G^+D@++\YO)%S*
M(WFFMJF@>:(A?I*\J99/LO,!RMHQ]OZ61JS'^L&:6MU;7=O'<VTJS02CE'*A
M#*P/<$9KY1(-'8NXA,2%@V"D'F'S1Y*TN_6WUJ2&.[9`ZB2+FQ0D@;\6S(PZ
M?+,7`&G"U6LT^*59".+W,BB='B5H_L,`5IML1MF,YP((V2/S!YZ\KZ`QCU&]
M5;@"OU:.KR[_`.2O3_99DX=)DR[Q&W>X6J[1P8-IRW_F_P`20P?G5Y(EE$;2
M7$()H)'B/'Z:$YDGLK,!R'S<&/M#IB:N0^#,M-U73=3M1=:?<QW5NVPDC8,*
M^!\#F!DQR@:D.$NWPYH9(\4#Q1160;7_TO5.*L0_-3\O[3SQY1N=(D(CO$_?
MZ=<?[[N$!XU_R6^P_P#DMEV#,<<K:LV,3C3X9O;*[L;R>RNXS#=VLC0W$3=5
M=#Q93](SH`;%AT9%&GJG_..GY<0^:?-3:MJ"J^DZ&R2-`Q!,MP=XE*]>"TYM
M_P`#F'K<_!&ASDY>CP\1L]'V#FE=L[%4#K__`!PM1_YA9O\`DVV2A]08RY%^
M=_\`NOZ,Z1T'5^A7E3_E%M'_`.8&V_Y,KG.9/J/O=_#Z0\J_YRN_\EW:?]M&
M'_B#YEZ#Z_@XVL^AXG_SCS_Y-W1?]6X_Y,MF?K?[LN%H_K?:N:)W#L5>)?GW
M_P`=S2_^89O^3ASH>Q?HE[WB_:C^\A_5_2B?('Y<P^9K/_$'F266?UR$M80Q
M3E''\(+$;\=J(JY#6ZXXCX>/:OJ;NS.R1J(^-G)EQ?3'^BR'7_R6\L7-E)^B
MD>QO54F%@[/&6IL'5RVQ_P`G,7!VMEB?5ZHN?JO9[!.)X!P38C^3WF2]TOS"
M_ER[<BVN6=$A;I'<IUX^'+BP.9W:N",\?B#F/]PZGL#62QYC@ERE_L<B'_/'
M_E+[?_F$3_B;8>QO[H_UF'M+_?C^K^MZ7YV\TOY<\FB[@I]=F2.&TY;@.RCX
MJ?Y"U;-3H]/XN7A/T_Q/2=I:W\OI^(?5M&+S;\N?R]/FR6XUO7)97L_4(V:D
MD\O5B7Z\!FWU^N\&H0Y_[AYSLGLK\U>7*3PW_IWH>H?E#Y(NK4PPV;6<H%$G
MA=^0/B0Q96^G-7#M/-$V3Q._R]A:64:$>'^E%Y=I&H:U^77G-["=N=HTBK=1
M]$EA8_#*H[,!O_PN;C+"&JP\0^KI_1E_->:T^7)V?J>"7T?Q?TH?SWT'ZJ>E
MZO(>GQY<NW&E:YR]/>6*M__3]4XJ\]_.W\RE\C^4GFMB&UK4";?34)^RQ'Q3
M$?RQ#?\`U^.9.EP>)+?Z0T:C+P1\WQ=%!J.HW$[QI+=W'&2YN&`+OQ7XI)&]
MA]IFS>[!TU&3*ORF_,&?R/YPMM5JS:;-^XU.%3]J!C]JG=HC\:Y1J</B1KJV
MZ?+P2?<EG=VUY:PW=K(LUM<(LD,J&JLC"JL#[C-"13N@;5<"4#K_`/QPM1_Y
MA9O^3;9*'U!C+D7YW_[K^C.D=!U?H5Y4_P"46T?_`)@;;_DRN<YD^H^]W\/I
M#RK_`)RN_P#)=VG_`&T8?^(/F7H/K^#C:SZ'B?\`SCS_`.3=T7_5N/\`DRV9
M^M_NRX6C^M]JYHG<.Q5XC^?G_';TS_F%?_B9SH>Q?HE[WC/:C^\A_5_WSUCR
MC;K;^5]*A44"6L6P]T!S2:F5Y)'^D7J=#'AP0']&*;92Y3YXN$]#\X.,`I35
MDH/]9QR_6<ZB)O2;_P`QX"0X>T=O]5_2COSQ_P"4OM_^85/^)ME78W]T?ZS?
M[2_W\?ZOZTU_/"9_T?Y?AWX%'<^%0BC*>QQZIERO:4G@QC\=&>_EE#'%Y%T@
M1BG*$NWNS.2<UVO-YI>]WG9$0-+"OYK)\PW9/#_S[B1=>TZ0#XGM&#>/PR&G
MZ\Z+L4^@C^D\5[3@>+`_T?TO1_K,_P#RK7U^1];]%UY=Z^CFIX1^8KIQ_P"^
M>BXY?D[_`(O"_P!Z_P#_U/4.I:C9:;87&H7TJP6=K&TT\SF@5$%2<(!)H()H
M67PQ^9_GZ]\[^;;K5YF862DPZ9;MTBME/P[?S/\`;D_RLW^GPC'&NKI,^7CE
M;WW_`)QK_+"'3?+<WF75H%>\UV+T[:*05X63=B#_`+_^TW^1QS7:[/<N$?PN
MPTF&HV>KPS\X/($ODGSI=:>B$:7<DW.E2'H87/V*^,3?`<V&FS>)"^O\3@ZG
M%P2\GKO_`#C!^9Z26_\`@;5)OWT7*719'/VH_M205/=/MQ_Y/+^7,/7Z?^,?
MYSEZ/-8X2^B,UCGH'7_^.%J/_,+-_P`FVR4/J#&7(OSO_P!U_1G2.@ZOT*\J
M?\HMH_\`S`VW_)E<YS)]1][OX?2'E7_.5W_DN[3_`+:,/_$'S+T'U_!QM9]#
MY\_*3S1I7E;S_INN:J76PM1,)3$I=_CC*BBCKN<V6IQF<"`Z_3Y!&5E](?\`
M0T7Y5_[]O?\`I%;^N:O\AD\G8_G(._Z&B_*O_?M[_P!(K?UQ_(9/)?SD&#_F
M!^8GEOSS?6UYH33-!:1&&8SQF(\F;D*`]=LW?9>"6.)OO>1]I,PGDA7\W]+V
MC\L_,=IK/E:T6-Q]:LHUM[N+]I604!_U6`JN:77X#CRF^4O5%Z3LC5QS8(T?
M5`<,F1ZEJ5EIME->WLJPVT"EY)&-!0?QS$A`S(B-R789<L<<3*1J(>$>0+:;
MS%^91U(J6ACFDOY2>PJ?3!_V17.DULABT_#Y<#P_9<#J-;XG0$Y/^)5_SQ_Y
M2^W_`.81/^)MD.QO[H_UFSVE_OX_U?ULL_.#1);WR=8ZA"O)M-*/*!U]*1`K
M'_8GCF%V5F$<IB?XW:]OZ8STXD/\G_N5;\EO,]I=Z"NB224O[`MPC8[O"S<@
M5\>)-#@[5TYCDX_X9_[IE[/:V,\/AD^O'_N'HSNJ(SN0JJ"68[``=23FJ>A)
MI\]_F'K*^;_.L-KI59X4X65JR_ML6)=Q_DU/_`KG4:'%X&$F>W\<G@>U<_YO
M5"./<?W<7NWZ)@_07Z)_W3]6^K?1PX9S?BGCX_/B>W\$>%P=.'@^Q__5Z_\`
MG=Y+\]^<M'MM#\NW-M:Z<[&34S.[(TO'^[C'%6^"OQ-_L<RM+DA`W)HU$)2%
M!Y-Y<_YQ4\TKKMD^O7=DVCI*'O8X'D,CQKOP6J*/C^R=_LYF3[0C1X>;B8]$
M0=^3Z@@AB@AC@A01PQ*$CC44"JHH`![#-3;LJ8)^<WY9KY\\K_5+8QQ:S9N)
M=-N9:A5)H'1BH)X.O_#<<R--G\.5]&C/AXXUU>(Z7_SC-^:NE:E;:GI^HZ=!
M?6<BS6THEEJKH:C_`'7]^9\M=CD*(+APTDXFP^H],;4&TZV.I)&E_P"FOUI8
M26C$M/BX$@'C7IFI-7L[(76[M4MI+K3+NVC($D\,D:$].3H5%?OQB:-J18?*
M/_0J7YC\*?7--K3_`'[+_P!4\V_Y^'FZS\E*WU5H=E+8Z+I]E,09;6VAAD*[
MJ6CC"FGM49J9&R2[.(H4PG\\/R_UKSQY3@TG2)((KF*[CN&:X9E3@BL#NH;?
MXLOTN88Y66G48S.-!X;_`-"I?F-_RV:;_P`C)?\`JGFP_E"'FX/Y&;O^A4OS
M&_Y;--_Y&2_]4\?Y0AYK^1F[_H5+\QO^6S3?^1DO_5/'^4(>:_D9LB\K?\XZ
M>>=*MYX[BYL6:1U9>$DA%`*=T&78NU,<1RDZO7]B9<T@8F/I_'<S;6ORF\PZ
M;>+J/E"[-N[(OK6RRF-E<#XN#]&0G]E\AA[2A./#F%_TD:CL3+CEQZ:7#_1O
MA2N7\OOS5\P.D.LW1%NAJ#<SAU'N$2M3EPUVFQ;P&_\`1#B2[+UVHVRR]/\`
M2E_Q+U'R9Y+TSROIQM[6LES+0W5TWVI&'_$5'[*YIM5JI9I6>7\,7I]!V?#3
M0X8\_P"*7\YB7YD?EMKWF77HK^PE@2%(%B(E9@W(,3V4^.9N@U\,,#&0/-U7
M:_9&74Y1*)C0C_$]%2TC>Q%K<(LB-&(Y4(JK#CQ8&O8YJN(W8>@$/31[GD_F
M3\F-3MK\ZAY4N>`#<X[9G,<D9_XKD[K_`*V;S!VK$CARCX_\=>6U?L_.,^/`
M>'^C]/#_`%9)?/Y._.358OJ=]<R&U;9Q+<KP(_R@I);+!JM)`\41O_5<>6@[
M1RCAE(\/]9G/D+\L=/\`+/\`IERZWFK,*">E$B!%"L8/_$\UVL[0EFV'I@[O
MLSL>&F]1]>3^=_-_JLWS7NY?_];U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BK__U_5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O__0]4XJ[%78J[%78J[%78J[%78J[%78
:J[%78J[%78J[%78J[%78J[%78J[%78J__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
